#Haematology #multiplemyeloma #Sanofi #Sarclisa #isatuximab #drugdelivery #UK #subcutaneousSarclisa #SarclisaOBI #theonbodyinjector #OBI #CirCLIQOBIdevice #CirCLIQOBI #antiCD38antibody #OBIdevice #NHS10YearPlan #NationalCancerPlan #patientcentredinnovation
zurl.co/SnRig
zurl.co/SnRig
UK will be first market for Sanofi's subcutaneous Sarclisa
Sanofi's on-body injector version of multiple myeloma therapy Sarclisa has been cleared in the UK, which will be the first market for the product.
pharmaphorum.com
June 19, 2026 at 9:07 AM
#Haematology #oncology #Talvey #Scotland #relapsedandrefractorymultiplemyeloma #multiplemyeloma #SMC #JnJ #ScottishMedicinesConsortium #NHSScotland #antiCD38antibody #bloodcancer #MonumenTAL1study #relapsedmyeloma #bispecifictherapy #MyelomaUK #GPRC5Dexpressingmyelomacells
zurl.co/YbEvY
zurl.co/YbEvY
Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma - PharmaTimes
SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments
pharmatimes.com
June 11, 2026 at 8:14 AM